摘要
目的探讨普瑞巴林治疗痛性糖尿病周围神经病变的效果。方法50例痛性糖尿病周围神经病变的患者，随机平分为两组，治疗组选用普瑞巴林150mg／d，无效时加量至300mg／d；对照组选用卡马西平200mg／d，无效时加量至600mg／d。疗程8周，评价两组的疗效及治疗前、后VAS评分。结果服药1周时疗效评估治疗组优于对照组（U=2．028，P=0．046），服药8周时疗效评估治疗组优于对照组（U=3．540，P〈0．001），差异均有统计学意义。服药1周时治疗组VAS评分低于对照组[（5．13±1．76）、（6．74±1．52）分，P〈0．05）]；服药8周时治疗组VAS评分低于对照组[（1．13±0．45）、（3．27±1．04），P〈0．05]。治疗组有5例（20％，5／25）患者出现不良反应，对照组有10例（40％，10／25）患者出现不良反应。结论普瑞巴林治疗痛性糖尿病周围神经病变具有良好的疗效。
Objective To observe the efficacy of pregabalin in the treatment of painful diabetic peripheral neuropathy. Methods In a 8-week study, 50 patients were randomly assigned into two groups ： the therapy group and the control group. The patients in the therapy group were treated with pregabalin 150 mg/d, and the patients in the control group were treated with carbamazepine 200 mg/d. The dose of pregabalin was increased to 300 mg/d till pain was alleviated in the therapy group, and the dose of carbamazepine was increased to 600 mg/d till pain was alleviated in the control group. The therapeutic effect and VAS score in the two groups were observed and evaluated. Results After 1 and 8 weeks＇ treatment, the therapeutic effect of therapy group were significantly superior to the control group （ At 1 week ： U = 2. 028, P = 0. 046 ; At 8 week ： U = 3. 540, P 〈 O. 001 ）. After 1 and 8 weeks＇ treatment,the VAS scores of therapy group were significantly lower than the control group （ At 1 week ：5.13± 1.76 vs. 6.74 ± 1.52,P 〈 0. 05 ; At 8 week ： 1.13± 0. 45 vs 3.27± 1.04,P 〈 0. 05 ）. There were 5 patients （20%） and 10 patients （40%） had adverse reaction in the therapy and the control groups respectively. Conclusion Pregabalin is effective and safe for the treatment of painful diabetic peripheral neuropathy.
出处
《中国综合临床》
2012年第10期1016-1019,共4页
Clinical Medicine of China
